Fifth Third Bancorp Decreases Stock Holdings in United Therapeutics Corporation $UTHR

Fifth Third Bancorp decreased its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 9.0% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 443 shares of the biotechnology company’s stock after selling 44 shares during the quarter. Fifth Third Bancorp’s holdings in United Therapeutics were worth $127,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. SVB Wealth LLC purchased a new position in United Therapeutics in the 1st quarter worth about $32,000. Geneos Wealth Management Inc. raised its position in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after buying an additional 85 shares during the last quarter. Sound Income Strategies LLC purchased a new stake in shares of United Therapeutics during the 1st quarter valued at about $49,000. Brooklyn Investment Group increased its position in shares of United Therapeutics by 103.2% during the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 98 shares during the last quarter. Finally, WPG Advisers LLC purchased a new stake in shares of United Therapeutics during the 1st quarter valued at about $60,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the company’s stock in a transaction that occurred on Thursday, August 21st. The stock was sold at an average price of $308.75, for a total value of $3,396,250.00. Following the completion of the transaction, the executive vice president owned 36,781 shares of the company’s stock, valued at $11,356,133.75. The trade was a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 223,435 shares of company stock valued at $86,811,362. 10.30% of the stock is currently owned by corporate insiders.

United Therapeutics Trading Up 4.5%

Shares of NASDAQ:UTHR opened at $438.18 on Thursday. The stock has a 50 day moving average of $350.60 and a 200 day moving average of $317.22. The company has a market cap of $19.77 billion, a PE ratio of 17.10, a price-to-earnings-growth ratio of 6.39 and a beta of 0.66. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $442.01.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). The company had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company’s revenue was up 11.7% compared to the same quarter last year. During the same quarter last year, the firm posted $5.85 earnings per share. Equities research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on UTHR. Wells Fargo & Company upped their price target on shares of United Therapeutics from $295.00 to $414.00 and gave the company an “equal weight” rating in a research report on Wednesday, September 3rd. Bank of America upped their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research report on Tuesday, September 2nd. Jefferies Financial Group upped their price target on shares of United Therapeutics from $432.00 to $564.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. UBS Group upped their price target on shares of United Therapeutics from $560.00 to $580.00 and gave the company a “buy” rating in a research report on Monday. Finally, Cantor Fitzgerald upped their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research report on Wednesday, September 10th. Ten equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $449.57.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.